ABSTRACT
4CPS-167 Figure 1 4CPS-167 Table 1Number of patients, administrations and days between each administration of ICIAtezolizumab Durvalumab Nivolumab Pembrolizumab Number of patients (%) 26 (10.24) 24 (9.45) 85 (33.46) 120 (47.24) Median number of administrations (IQR) 4 (3-8) 13 (5-24) 7 (3-22) 6 (3-13) Mean days between administrations (SD) 24 (7.43) 18 (7.67) 22 (31.38) 25 (15.99) We can see a significate decrease on the number of patients treated with an ICI between May 2020 and August 2020, possibly influenced by the decrease in the number of patients diagnosed with NSCLC during the COVID-19 pandemic.The mean days between each ICI administration was slightly above the approved posology, possibly due to delays because of adverse effects.References and/or AcknowledgementsConflict of InterestNo conflict of interest